Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-007 DNA vaccine booster for COVID-19
NCT05685953Phase 1Completed
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OC-007 in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Local reactions after the vaccine/placebo dose at 7 days, Visual analogue scale pain rating scale score at 60 minutes and 3 more. Started Feb 2023; status: completed.
02
Drugs
OC-007
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05685953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685953.